The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS
Open accessAbstract
Context: Denosumab discontinuation is characterized by an increase in bone turnover overriding pretreatment status, a rapid bone loss in the majority and multiple vertebral fractures (VFx) in some patients. Methods: A working group of the European Calcified Tissue Society performed an updated systematic review of existing literature on changes of bone turnover, bone mineral density (BMD), and fracture risk after denosumab discontinuation and provided advice on management based on expert opinion. Results: Important risk factors for multiple VFx following denosumab cessation are prevalent VFx, longer duration off therapy, greater gain in hip BMD during therapy, and greater loss of hip BMD after therapy according to a retrospective analysis of the FREEDOM Extension Study. Case series indicate that prior bisphosphonate therapy mitigates the biochemical rebound phenomenon after denosumab discontinuation, but it is uncertain whether this attenuation prevents BMD loss and fractures. Current evidence indicates partial efficacy of subsequent antiresorptive treatment with results seemingly dependent on duration of denosumab treatment. Conclusions: A careful assessment of indications to start denosumab treatment is advised, especially for younger patients. A case for long-term treatment with denosumab can be made for patients at high fracture risk already on denosumab treatment given the favorable efficacy and safety profile. In case of denosumab discontinuation, alternative antiresorptive treatment should be initiated 6 months after the final denosumab injection. Assessment of bone turnover markers may help define the optimal regimen, pending results of ongoing randomized controlled trials. Patients who have sustained VFx should be offered prompt treatment to reduce high bone turnover.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Self-citationRomosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationDenosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Bone, H. G., Wagman, R. B., Brandi, M. L., Brown, J. P., Chapurlat, R., Cummings, S. R., Czerwiński, E., Fahrleitner-Pammer, A., Kendler, D. L., Lippuner, K., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30138-9 · Cited by 996
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00221 · Cited by 868
Self-citationCummings, S. R., Ferrari, S., Eastell, R., Gilchrist, N., Jensen, J.-E. B., McClung, M., Roux, C., Törring, O., Valter, I., Wang, A. T., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3337 · Cited by 734
Self-citationAdler, R. A., El-Hajj Fuleihan, G., Bauer, D. C., Camacho, P. M., Clarke, B. L., Clines, G. A., Compston, J. E., Drake, M. T., Edwards, B. J., Favus, M. J., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2708 · Cited by 672
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Miller, P. D., Yang, Y.-C., Grazette, L., San Martin, J., & Gallagher, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1502 · Cited by 623
Brown, J. P., Prince, R. L., Deal, C., Recker, R. R., Kiel, D. P., de Gregorio, L. H., Hadji, P., Hofbauer, L. C., Álvaro-Gracia, J. M., Wang, H., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0809010 · Cited by 610
Self-citationLeder, B. Z., Tsai, J. N., Uihlein, A. V., Wallace, P. M., Lee, H., Neer, R. M., & Burnett-Bowie, S.-A. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61120-5 · Cited by 603
Miller, P. D., Bolognese, M. A., Lewiecki, E. M., McClung, M. R., Ding, B., Austin, M., Liu, Y., & San Martin, J. (2008) · Bone · doi:10.1016/j.bone.2008.04.007 · Cited by 578
The Functional and Clinical Significance of the 24-Hour Rhythm of Circulating Glucocorticoids
Oster, H., Challet, E., Ott, V., Arvat, E., de Kloet, E. R., Dijk, D.-J., Lightman, S., Vgontzas, A., & Van Cauter, E. (2017) · Endocrine Reviews · doi:10.1210/er.2015-1080 · Cited by 548
Tsourdi, E., Langdahl, B., Cohen-Solal, M., Aubry-Rozier, B., Eriksen, E. F., Guañabens, N., Obermayer-Pietsch, B., Ralston, S. H., Eastell, R., & Zillikens, M. C. (2017) · Bone · doi:10.1016/j.bone.2017.08.003 · Cited by 504
Self-citationKendler, D. L., Roux, C., Benhamou, C. L., Brown, J. P., Lillestol, M., Siddhanti, S., Man, H.-S., Martin, J. S., & Bone, H. G. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090716 · Cited by 453
Shoback, D., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Eastell, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa048 · Cited by 439
Self-citationBone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
Langdahl, B., Ferrari, S., & Dempster, D. W. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16670154 · Cited by 432
Self-citationAnastasilakis, A. D., Polyzos, S. A., Makras, P., Aubry‐Rozier, B., Kaouri, S., & Lamy, O. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3110 · Cited by 371
Self-citationon behalf of the DAPS Investigators, Freemantle, N., Satram-Hoang, S., Tang, E.-T., Kaur, P., Macarios, D., Siddhanti, S., Borenstein, J., & Kendler, D. L. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1780-1 · Cited by 288
Observations following discontinuation of long-term denosumab therapy
McClung, M. R., Wagman, R. B., Miller, P. D., Wang, A., & Lewiecki, E. M. (2017) · Osteoporosis International · doi:10.1007/s00198-017-3919-1 · Cited by 227
Lamy, O., Gonzalez-Rodriguez, E., Stoll, D., Hans, D., & Aubry-Rozier, B. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3170 · Cited by 191
Self-citationNaylor, K. E., Jacques, R. M., Paggiosi, M., Gossiel, F., Peel, N. F. A., McCloskey, E. V., Walsh, J. S., & Eastell, R. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3145-7 · Cited by 170
Self-citationCummings, S. R., Cosman, F., Lewiecki, E. M., Schousboe, J. T., Bauer, D. C., Black, D. M., Brown, T. D., Cheung, A. M., Cody, K., Cooper, C., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3039 · Cited by 165
Self-citationAnastasilakis, A. D., Papapoulos, S. E., Polyzos, S. A., Appelman-Dijkstra, N. M., & Makras, P. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3853 · Cited by 162
Self-citationPopp, A. W., Zysset, P. K., & Lippuner, K. (2016) · Osteoporosis International · doi:10.1007/s00198-015-3458-6 · Cited by 159
DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?
Eastell, R., Pigott, T., Gossiel, F., Naylor, K. E., Walsh, J., & Peel, N. F. A. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0585 · Cited by 155
Self-citationBrown, J. P., Roux, C., Törring, O., Ho, P., Jensen, J. B., Gilchrist, N. L., Recknor, C. P., Austin, M., Wang, A., Grauer, A., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1808 · Cited by 153
Kendler, D. L., Bone, H. G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S. V., Dinavahi, R. V., Libanati, C. R., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05146-9 · Cited by 131
Bone Mineral Density After Transitioning From Denosumab to Alendronate
Kendler, D. L., Chines, A. A., Clark, P., Ebeling, P. R., McClung, M. R., Rhee, Y., Huang, S., & Stad, R. K. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz095 · Cited by 127
Ferrari, S., Libanati, C. R., Lin, C. J. F., Brown, J. P., Cosman, F., Czerwinski, E. J., de Gregorio, L. H., Malouf, J., Reginster, J.-Y., Wang, A., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3722 · Cited by 123
Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
Zanchetta, M. B., Boailchuk, J., Massari, F., Silveira, F., Bogado, C., & Zanchetta, J. R. (2018) · Osteoporosis International · doi:10.1007/s00198-017-4242-6 · Cited by 119
Bone Loss After Denosumab: Only Partial Protection with Zoledronate
Reid, I. R., Horne, A. M., Mihov, B., & Gamble, G. D. (2017) · Calcified Tissue International · doi:10.1007/s00223-017-0288-x · Cited by 119
Leder, B. Z., Tsai, J. N., Jiang, L. A., & Lee, H. (2017) · Bone · doi:10.1016/j.bone.2017.03.006 · Cited by 112
Lamy, O., Stoll, D., Aubry‐Rozier, B., & Rodríguez, E. G. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00502-4 · Cited by 110
McClung, M. R. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3553-3 · Cited by 107
Everts‐Graber, J., Reichenbach, S., Ziswiler, H. R., Studer, U., & Lehmann, T. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3962 · Cited by 100
Dempster, D. W., Brown, J. P., Fahrleitner‐Pammer, A., Kendler, D. L., Rizzo, S., Valter, I., Wagman, R. B., Yin, X., Yue, S. V., & Boivin, G. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02669 · Cited by 97
Bone Loss After Romosozumab/Denosumab: Effects of Bisphosphonates
Horne, A. M., Mihov, B., & Reid, I. R. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0404-6 · Cited by 95
Anastasilakis, A. D., Yavropoulou, M. P., Makras, P., Sakellariou, G. T., Papadopoulou, F. G., Gerou, S., & Papapoulos, S. E. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-1027 · Cited by 88
Self-citationBrown, J. P., Dempster, D. W., Ding, B., Dent-Acosta, R. E., Martín, J. S., Grauer, A., Wagman, R. B., & Zanchetta, J. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.448 · Cited by 87
Popp, A. W., Varathan, N., Buffat, H., Senn, C., Perrelet, R., & Lippuner, K. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0394-4 · Cited by 85
New and emerging concepts in the use of denosumab for the treatment of osteoporosis
Lewiecki, E. M. (2018) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x18805759 · Cited by 82
Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider
Tripto‐Shkolnik, L., Fund, N., Rouach, V., Chodick, G., Shalev, V., & Goldshtein, I. (2019) · Bone · doi:10.1016/j.bone.2019.115150 · Cited by 81
Dempster, D. W., Zhou, H., Recker, R. R., Brown, J. P., Bolognese, M. A., Recknor, C. P., Kendler, D. L., Lewiecki, E. M., Hanley, D. A., Rao, D. S., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1262 · Cited by 80
Treat-to-target for Osteoporosis: Is Now the Time?
Lewiecki, E. M., Cummings, S. R., & Cosman, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3680 · Cited by 75
Uebelhart, B., Rizzoli, R., & Ferrari, S. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4080-6 · Cited by 73
Goal-directed treatment of osteoporosis in Europe
Kanis, J. А., McCloskey, E. V., Branco, J., Brandi, M. L., Dennison, E. M., Devogelaer, J.-P., Ferrari, S., Kaufman, J., Papapoulos, S. E., Reginster, J., et al. (2014) · Osteoporosis International · doi:10.1007/s00198-014-2787-1 · Cited by 72
Self-citationFracture risk following intermission of osteoporosis therapy
On behalf of the IOF Epidemiology/Quality of Life Working Group, Dennison, E. M., Cooper, C. C., Kanis, J. A., Bruyère, O., Silverman, S. S., McCloskey, E. V., Abrahamsen, B., Prieto‐Alhambra, D., & Ferrari, S. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05002-w · Cited by 68
Self-citationGoal-directed treatment of osteoporosis
Cummings, S. R., Cosman, F., Eastell, R., Reid, I. R., Mehta, M., & Lewiecki, E. M. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1854 · Cited by 62
Self-citationPossible protective effect of switching from denosumab to zoledronic acid on vertebral fractures
Lehmann, T., & Aeberli, D. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4108-y · Cited by 58
Rodríguez, E. G., Aubry‐Rozier, B., Stoll, D., Zaman, K., & Lamy, O. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05458-8 · Cited by 57
Tripto‐Shkolnik, L., Rouach, V., Marcus, Y., Rotman‐Pikielny, P., Benbassat, C. A., & Vered, I. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0389-1 · Cited by 51
Meier, C., Uebelhart, B., Aubry‐Rozier, B., Birkhuser, M., Bischoff-Ferrari, H. A., Frey, D., Kressig, R. W., Lamy, O., Lippuner, K., Stute, P., et al. (2017) · Swiss Medical Weekly · doi:10.4414/smw.2017.14484 · Cited by 48
Self-citationModeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab
Dempster, D. W., Chines, A. A., Bostrom, M. P., Nieves, J. W., Zhou, H., Chen, L., Pannacciulli, N., Wagman, R. B., & Cosman, F. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4006 · Cited by 47
Makras, P., Papapoulos, S. E., Pοlyzos, S. A., Appelman‐Dijkstra, N. M., & Anastasilakis, A. D. (2020) · Bone · doi:10.1016/j.bone.2020.115478 · Cited by 44
Self-citationJähn, K., Wölfel, E. M., Jobke, B., Riedel, C., Hellmich, M., Werner, M., McDonald, M. M., & Busse, B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00250 · Cited by 42
Fassio, A., Adami, G., Benini, C., Vantaggiato, E., Saag, K. G., Giollo, A., Lippolis, I., Viapiana, O., Idolazzi, L., Orsolini, G., et al. (2019) · Bone · doi:10.1016/j.bone.2019.03.019 · Cited by 37
Lamy, O., Fernández-Fernández, E., Monjo, I., Stoll, D., Aubry‐Rozier, B., Benavent-Núñez, D., Aguado, P., & Rodríguez, E. G. (2019) · Osteoporosis International · doi:10.1007/s00198-018-04820-8 · Cited by 34
Anastasilakis, A. D., Evangelatos, G., Makras, P., & Iliopoulos, A. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100267 · Cited by 32
Self-citationEffect of risedronate on bone loss at discontinuation of denosumab
Laroche, M., Couture, G., Ruyssen‐Witrand, A., Constantin, A., & Degboé, Y. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100290 · Cited by 31
Kashii, M., Ebina, K., Kitaguchi, K., & Yoshikawa, H. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100288 · Cited by 30
Flórez, H., Ramírez, J., Monegal, A., Guañabens, N., & Peris, P. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.02.007 · Cited by 29
Self-citationCertainties and Uncertainties About Denosumab Discontinuation
Tsourdi, E. A., & Zillikens, M. C. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0436-y · Cited by 24
Self-citationUnderestimation of Vertebral Fractures After Denosumab Discontinuation
Lamy, O., & Rodríguez, E. G. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3370 · Cited by 22
Rodríguez, E. G., Stoll, D., & Lamy, O. (2018) · Case Reports in Rheumatology · doi:10.1155/2018/5432751 · Cited by 22
Ramchand, S. K., David, N. L., Leder, B. Z., & Tsai, J. N. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz163 · Cited by 15
Hip fractures following denosumab discontinuation: three clinical cases reports
Henríquez, M. S., Romero, M. J. G. D. T., Escudero-Socorro, M., & Suau, Ó. T. (2019) · Journal of the Royal Society of Medicine · doi:10.1177/0141076819861027 · Cited by 13
Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?
Anastasilakis, A. D., Tournis, S., Yavropoulou, M. P., Pοlyzos, S. A., & Makras, P. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0409-1 · Cited by 9
Self-citation
Cited by
Drug therapy for osteoporosis in older adults
Reid, I. R., & Billington, E. O. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02646-5 · Cited by 698
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
Self-citationBone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaca, T., Gossiel, F., Salam, S., & Eastell, R. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 387
Self-citationWalker, M. D., & Shane, E. (2023) · New England Journal of Medicine · doi:10.1056/nejmcp2307353 · Cited by 381
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Self-citation
Metadata
- Authors
- Tsourdi, E., Zillikens, M. C., Meier, C., Body, J.-J., Gonzalez Rodriguez, E., Anastasilakis, A. D., Abrahamsen, B., McCloskey, E., Hofbauer, L. C., Guañabens, N., Obermayer-Pietsch, B., Ralston, S. H., Eastell, R., Pepe, J., Palermo, A., & Langdahl, B.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-10-26
- Volume
- 106
- Issue
- 1
- Pages
- 264-281
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W3094494322
- Cited by
- 375
- References
- 67
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.